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Figure 1: The patient’s bone
marrow biopsy demonstrating
hemophagocytosis of platelets
(short arrow) and erythrocytes
(long arrows).

Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare
syndrome of immune dysregulation that is often
recognized as secondary to an underlying immune
activating state, such as malignancy, rheumatologic
disorders, and infections. This case highlights an
association between HLH and human immunodeficiency virus (HIV) infection. Although HLH is a rare
complication of HIV, it presents a difficult challenge for
treatment. Without treatment, HLH is invariably fatal, but
the consequence of the immunosuppressive treatment
regimen in the setting of an underlying opportunistic
infection can also have fatal outcomes.

Case Presentation
A 38 year-old man with a history of HIV infection with a
CD4 lymphocyte count of 2 cells/mm3 presented with
fevers two weeks after starting antiretroviral therapy
(ART). His initial extensive infectious workup was
negative, including cryptococcal antigen in the serum
and cerebrospinal fluid. His liver enzymes then began

to rise, prompting concern for drug toxicity. At this
time, ART and trimethoprim/sulfamethoxazole were
discontinued, but he continued to have high-grade
fevers as well as hypotension, pancytopenia and
hypofibrinogenemia and was transferred to the medical
intensive care unit (MICU). On admission to the MICU, he
was febrile with a temperature of 103.6°F, hypotensive
with a blood pressure of 78/37 mmHg, tachycardic with
a heart rate of 127 beats per minute, tachypneic with a
respiratory rate of 26 breaths per minute, and had an
oxygen saturation of 97% on room air. On exam, he
was thin, in moderate distress, and lethargic. He had
no thrush or nuchal rigidity. He had cervical lymphadenopathy and hyperpigmented maculopapular rashes
on his lower extremities; otherwise his exam was
unremarkable.

Differential Diagnosis
The differential diagnosis included opportunistic
infections given his CD4 count of 2 cells/mm3, immune
reconstitution inflammatory syndrome (IRIS) given his
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Table 1: Diagnostic Criteria for HLH3
Diagnosis of HLH requires
Molecular diagnosis consistent with HLH

were negative. He was transferred back to the MICU,
initiated on intravenous amphotericin B/flucytosine,
and ART was discontinued. However, he continued to
decompensate rapidly and expired from septic shock
and acute pulmonary edema later that day.

-ORFulfillment of 5 of the 8 criteria listed below:
1. Fever > 38.5C
2. Splenomegaly
3. C
 ytopenias (affecting at least 2 of 3 lineages
Hemoglobin < 9 g/dL
Platelets < 100 x 103/mL
Neutrophils < 1 x 103/mL)
4. H
 ypertriglyceridemia (fasting > 265 mg/dL) and/or
hypofibrinogenemia (< 150 mg/dL)
5. H
 emophagocytosis in bone marrow, spleen, lymph
nodes, or liver
6. Low or absent NK-cell activity
7. Ferritin > 500 ng/mL
8. Elevated sCD25 (α-chain of sIL-2 receptor)

recent initiation of ART, drug reaction or toxicity, and
hemophagocytic lymphohistiocytosis (HLH). Further
laboratory studies revealed an elevated ferritin level of
83,987 ng/mL (normal range = 30-400), which was
highly suspicious for HLH. The diagnosis was confirmed
with a bone marrow biopsy revealing hemophagocytosis
(Figure 1) as well as an elevated interleukin 2 receptor
(IL2R) level of 9020 pg/mL (normal range = 0-1033).

Outcome and Follow-up
The patient was treated with intravenous immunoglobulin, high dose dexamethasone, and anakinra,
an IL1R inhibitor, resulting in cessation of his fevers,
resolution of his respiratory distress, and improvement
in his cell lines. He was transferred back to the floors
with plans to restart ART. As no underlying infection had
been found, his HLH was thought to be secondary to
his HIV infection. However, three days later, he became
acutely short of breath and hypotensive and was found
to have Cryptococcus neoformans fungemia, although
his initial blood and cerebrospinal fluid fungal studies
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Discussion
Hemophagocytic lymphohistiocytosis (HLH) is a severe
and rapidly progressive disorder of immune activation
and dysregulation that can occur as a familial disorder
or, as is becoming increasingly recognized, secondary
to a variety of underlying conditions. Secondary HLH
occurs after strong immunologic activation, such as
with severe infection, immunodeficiency, or underlying
malignancy. In the past, HLH was also sometimes
referred to as hemophagocytic syndrome. Another
disorder on the spectrum of this disease state includes
macrophage activation syndrome, which is a form of
HLH associated with rheumatologic diseases.1 Although
the immune cells in HLH are functionally normal, it is
thought to be the result of proliferation of activated T
cells that go on to activate macrophages, as well as
the lack of appropriate apoptosis of immunogenic cells.
As these overly active macrophages and histiocytes
proliferate and run rampant, they phagocytize other
cells, including erythrocytes, leukocytes, and platelets,
leading to the clinical symptoms. This highly stimulated
immune system results in life-threatening cytokine
storm and inflammatory reactions.1,2
As the clinical entity of HLH is a syndrome, it has
features that can be seen in other clinical states, but it
is the combination of findings that make the diagnosis
likely. The diagnostic criteria for HLH include fever,
splenomegaly, cytopenia of at least 2 of 3 cell lines,
elevated ferritin, hypofibrinogenemia and/or hypertriglyceridemia, elevated CD 25 (IL-2 receptor), low or
absent natural killer (NK) cells, and hemophagocytosis
seen in the bone marrow, liver, spleen, or lymph nodes.
Five of these eight criteria must be met in order to
establish the diagnosis (Table 1).3 Notably, the criteria
only require a ferritin level >500 ng/mL, but a level
>10,000 ng/mL is thought to be highly suspicious for
HLH, with a specificity of 96%.4 The ferritin level upon
diagnosis has also been found to have prognostic value,
and its decline correlates with response to treatment.
The soluble IL-2 receptor was found to be a more
sensitive marker than ferritin with a sensitivity of 93%
and also carries prognostic implications.5

Without therapy, HLH is uniformly fatal. Treatment
includes supportive care, immunomodulatory therapy,
and treatment of any underlying condition. For the
familial form of HLH, the treatment backbone is an
induction phase involving chemotherapy, typically
etoposide, combined with immunotherapy, such
as cyclosporine A and steroids. This is followed by a
continuation phase that is to be maintained until stem
cell transplant is available, as transplant is the only
curative treatment for familial HLH. The treatment for
secondary HLH is not as well defined as it can vary based
on the associated disease. For underlying malignancies,
the treatment approach is often similar to the familial
form, with chemotherapy and immunotherapy. For
the secondary forms associated with immunodeficiency or rheumatologic causes, the approach relies
more heavily on immunomodulators, such as the IL-1
receptor antagonist anakinra.2
In the context of HIV, HLH has been reported to occur
secondary to opportunistic infections, as well as from
HIV infection itself, both during the acute seroconversion phase and the profoundly immunosuppressed
state.6,7 Given the non-specific clinical manifestations
of HLH and the otherwise heightened concern for
opportunistic infections, one must have a high clinical
suspicion for recognizing this disease in the setting of
HIV. Treating HLH in the setting of severe immunosuppression from HIV presents a difficult challenge, as with
this patient. As induction treatment for HLH requires
high dose steroids and IV immunoglobulin to quell
the life-threatening inflammatory response, underlying
opportunistic infections may prove to be fatal if they
go unrecognized. There are no current guidelines on
antibiotic use in HIV patients with confirmed HLH, and
it may be of value to treat these patients empirically for
opportunistic infections in the setting of critical illness.

Key Points
Patients presenting with a clinical picture of fever and
highly elevated inflammatory markers should raise the
suspicion for hemophagocytic lymphohistiocytosis
(HLH). Five of the eight criteria must be met for the
diagnosis, but a ferritin level >10,000 ng/mL is highly
suspicious. HLH is fatal without treatment, but immunomodulatory therapy directed at HLH may be perilous in
the setting of underlying infection. Currently, there are
no guidelines on empiric antibiotic use for patients with
HIV and HLH, but one must be vigilant in searching for
underlying infections given the risk of the immunosuppressive regimen required to treat HLH in the setting
of HIV.
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